Life Sciences

MaaT Pharma announces €10 million fundraising and pursues the development of the first worldwide autologous microbiotherapy solution
22 March 2016

MaaT Pharma announces €10 million fundraising and pursues the development of the first worldwide autologous microbiotherapy solution

MaaT Pharma, a reference for the microbiome industry, is announcing a significant €10 million fundraising operation within the context of its series A. This will notably...

Read the press release
TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease
4 December 2014

TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory...

Read the press release